Posts Tagged ‘treatment’

Study: Osteoporosis drug benefits mesothelioma patients

10 Jul 2017 by under Research/Treatment

Bone Comparison of Healthy and Osteoporotic Vertibrae edited1 100x100 Study: Osteoporosis drug benefits mesothelioma patientsWhen the creation of new bone is outpaced by removal of the old, a condition called osteoporosis occurs, which causes weak and brittle bones. Researchers at the University of Alabama have recently linked the benefits of a drug used to treat and prevent osteoporosis to . (more…)


Multiple sclerosis drug could hold promise as mesothelioma treatment

28 Mar 2017 by under Research/Treatment

Gilenya 05 mg Hartkapselen Fingolimod 100x100 Multiple sclerosis drug could hold promise as mesothelioma treatmentStandard first-line for , a deadly cancer caused by exposure to asbestos, is chemotherapy that generally only extends patients’ lives by 11 weeks.

Because treatment options for malignant mesothelioma are few, researchers are now looking at more innovative, novel approaches to treat the disease. For example, a multiple sclerosis (MS) treatment has recently found promise as a potential malignant mesothelioma (MM) treatment, according to Mesothelioma Research News. When used in mice, it was found to reduce tumor size with no apparent side effects. (more…)


Residency during mesothelioma diagnosis crucial to application of law, judge says

9 Feb 2017 by under Legal

445px Altan 100x100 Residency during mesothelioma diagnosis crucial to application of law, judge saysFor some, potential exposure to , a known human carcinogen used in a wide variety of products and trades, occurs over a lifetime—each job runs the risk of exposure. What happens if that exposure occurs in different states during a person’s career and he eventually develops ? A judge had to determine the answer to that question last month when, in a pending case, asbestos exposure allegedly occurred in both Tennessee and Virginia, according to Lexis Legal News. (more…)


Pleural mesothelioma WT1 vaccine is renamed “galinpepimut-S”

8 Apr 2016 by under Research/Treatment

research test tubes 100x100 Pleural mesothelioma WT1 vaccine is renamed galinpepimut SA clinical-stage immunotherapy to be used for the of malignant pleural mesothelioma, as well as a wide range of hematologic cancers and solid tumors, has been dubbed “galinpepimut-S” by the United States Adopted Named Council of the American Medical Association. (more…)


Mesothelioma research sees possible breakthrough following study of patient tumors

2 Mar 2016 by under Research/Treatment

mesothelioma tumor wikipedia 100x100 Mesothelioma research sees possible breakthrough following study of patient tumorsIt’s comes as no surprise that the rare and deadly cancer has researchers scrambling to learn new ways of treating patients suffering with advanced forms of the disease. However, a new discovery by a team of physician-researchers from the at Brigham and Women’s Hospital (BWH) may have uncovered a new piece of the puzzle. (more…)


Access to mesothelioma treatment limited, difficult

13 Jul 2009 by under Events, News, Research/Treatment

Among the most interesting discussions at the recent International Symposium on Malignant Mesothelioma, held in Washington, D.C., June 25-27, was a panel discussion about the challenges of finding treatment once a patient is diagnosed with mesothelioma. The panel featured physicians from three of the leading programs in treating peritoneal mesothelioma, Dr. Paul Sugarbaker, , and Dr. John Chabot.

Peritoneal mesothelioma affects the lining of the abdomen, and makes up about 10-15 percent of all mesothelioma diagnoses. The more common form of mesothelioma is pleural, which affects the lining of the chest and lungs. All mesothelioma is linked to asbestos exposure.

The current “best practice” for the treatment of mesothelioma is a multi-modality approach, which is a combination of surgery and , along with immunotherapy.

“It’s a sequence of treatments that make sense,” Dr. Chabot explained.

However, Dr. Sugarbaker pointed out, only a small fraction of mesothelioma patients receive multimodality treatment.

“So many more things could be done to manage the treatment of this rare disorder,” Dr. Sugarbaker said. “We should have accumulated many thousands of data points on people with peritoneal mesothelioma. Unfortunately, a majority of patients in the U.S. do not get to a treatment center.”

There are still only a handful of treatment centers that specialize in mesothelioma, and even then there are distinctions in the treatment of peritoneal or pleural mesothelioma that narrows the field even further. Also, there are not a large number of physicians currently treating mesothelioma, and no established surgical training programs specifically for this field to develop more doctors experienced in mesothelioma treatment.

Awareness also is still an issue. Many patients are diagnosed too late for effective treatment.

Even if awareness is high and a patient is diagnosed early enough to be a viable candidate for successful mesothelioma treatment, the logistics of receiving treatment can be difficult. Most of the centers for mesothelioma treatment are located on the East Coast. There is one on the West Coast, but almost no options in the Midwest or other areas of the country. Treatment is usually extended over many months, making it necessary for patients to relocate to be near a treatment center if they are not lucky enough to live nearby.

“People often move and rent temporary housing. People live in trailers,” Dr. Chabot said. “More advocacy is needed to provide patient and family support for treatment. The travel issues for people who need treatment are huge.”

The Mesothelioma Applied Research Foundation, which sponsors the annual Meso Symposium, is laying the groundwork to facilitate discussions and establish a collaborative strategy, simply by bringing together the experts in this field. There is an emphasis now on forming a consortium to establish a new standard of care, and to try to combine the knowledge of the existing research and treatment centers, and to expand access to that research and treatment.

But, the experts acknowledge, there is still much to do.